SCHEMBL3070928

SCHEMBL3070928

COC(=O)[C@@H](C=Cc1ccccc1)Oc1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 4/20 0.49
NOS1 P29475 4/20 0.49
NOS2 P35228 4/20 0.49
CYP1A1 P04798 2/20 0.46
MAOB P27338 2/20 0.46
CYP1B1 Q16678 2/20 0.46
PPARG P37231 3/20 0.45
PPARA Q07869 2/20 0.45
SLC6A9 P48067 1/20 0.41
NPC1 O15118 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
MTOR P42345 2/20 0.41
RAB9A P51151 2/20 0.41
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11988775 1.00 NOS3 (0.49) NOS3NOS1NOS2CYP1A1MAOB
SCHEMBL3062675 0.87 PPARG (0.52) CYP1A1MAOBCYP1B1PPARGPPARA
SCHEMBL11988779 0.87 PPARG (0.52) CYP1A1MAOBCYP1B1PPARGPPARA
SCHEMBL3062673 0.87 PPARG (0.52) CYP1A1MAOBCYP1B1PPARGPPARA
SCHEMBL5693157 0.87 CNR2 (0.43) MAOBCYP1B1PPARGPPARANPC1
SCHEMBL5693154 0.87 CNR2 (0.43) MAOBCYP1B1PPARGPPARANPC1
SCHEMBL3062710 0.76 CYP1A2 (0.46) MAOBCYP1B1CYP2D6MEN1CYP1A2
SCHEMBL5693176 0.76 CYP1A2 (0.46) MAOBCYP1B1CYP2D6MEN1CYP1A2
SCHEMBL3070932 0.74 PPARG (0.47) CYP1A1CYP1B1PPARGPPARASLC6A9
SCHEMBL6202805 0.73 NOS3 (0.50) NOS3NOS1NOS2CYP1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247448-B2 Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes MERCK PATENT GMBH (DE) 2012-08-21 US disclosed
US-7820847-B2 Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia, atherosclerosis and diabetes MERCK PATENT GMBH (DE) 2010-10-26 US disclosed
US-20100261789-A1 Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes ZEILLER JEAN-JACQUES 2010-10-14 US disclosed
US-20060178434-A1 Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes MERCK PATENT GMBH (DE) 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261789-A1 Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes ALOX15, LIPA, APOB NOS3 831/4885NOS1 982/4885NOS2 1384/4885
US-20060178434-A1 Butenoic acid derivatives processes for the preparation thereof pharmaceutical compositions comprising them and use for the treatment of dyslipidaemia atherosclerosis and diabetes APOB, ALOX15, GPR119 NOS3 731/4885NOS1 855/4885NOS2 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.